SEARCH

SEARCH BY CITATION

References

  • 1
    Williams R. Global challenges in liver disease. Hepatology 2006; 44: 5216.
  • 2
    McCaughan GW, Omata M, Amarapurkar D, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22: 61533.
  • 3
    Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 52938.
  • 4
    Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36: S304.
  • 5
    Mostafa A, Mohamed MK, Saeed M, et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 2010; 59: 113540.
  • 6
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 133574.
  • 7
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 24564.
  • 8
    Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006; 45: 20413.
  • 9
    Bruno R, Sacchi P, Scagnolari C, et al. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study. Aliment Pharmacol Ther 2007; 26: 36976.
  • 10
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 95865.
  • 11
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 12
    McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 58093.
  • 13
    Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009; 49: 2231.
  • 14
    Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138: 11622.
  • 15
    Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138: 10815.
  • 16
    Jin Y-J, Lee J-W, Lee JI, et al. Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population. BMC Gastroenterol 2013; 13: 74.
  • 17
    Dogan UB, Atabay A, Akin MS, Yalaki S. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1. Eur J Gastroenterol Hepatol 2013; 20: 10825.
  • 18
    Almasio PL, Cavalletto L, Chemello L, et al. Efficacy of PEG-IFN alfa-2b vs. PEG-IFN alfa-2a + ribavirin regimens in treatment-naïve chronic HCV patients: a cumulative meta-analysis of retrospective data from 6 clinic sites. Gastroenterology 2006; 130: A842.
  • 19
    Druyts E, Mills EJ, Nachega J, O'Regan C, Cooper CL. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clin Exp Gastroenterol 2012; 5: 1121.
  • 20
    Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010; 51: 117684.
  • 21
    Zhao S, Liu E, Chen P, et al. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: a meta-analysis of randomized trials. Clin Ther 2010; 32: 156577.
  • 22
    Singal AK, Jampana SC, Anand BS. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig Dis Sci 2011; 56: 22216.
  • 23
    Flori N, Funakoshi N, Duny Y, et al. Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C: a meta-analysis. Drugs 2013; 73: 26377.
  • 24
    Gad RR, Males S, El Makhzangy H, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008; 28: 11129.
  • 25
    Kamal SM, Ahmed A, Mahmoud S, et al. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis. Liver Int 2011; 31: 40111.
  • 26
    El Raziky M, Fathalah WF, El-Akel WA, et al. The effect of peginterferon alpha-2a vs. peginterferon alpha-2b in treatment of naive chronic HCV genotype-4 patients: a single centre Egyptian study. Hepat Mon 2013; 13: e10069.
  • 27
    Papastergiou V, Dimitroulopoulos D, Skorda L, et al. Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? J Med Virol 2012; 84: 121723.
  • 28
    Derbala MF, Al Kaabi SR, El Dweik NZ, et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006; 12: 56928.
  • 29
    Males S, Gad RR, Esmat G, et al. Serum α -foetoprotein level predicts treatment. Antivir Ther 2007; 12: 797803.
  • 30
    Ferenci P, Laferl H, Scherzer T-M, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 4518.
  • 31
    El Makhzangy H, Esmat G, Said M, et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 2009; 1583: 157683.
  • 32
    Varghese R, Al-Khaldi J, Asker H, et al. Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin. Hepatogastroenterology 2009; 56: 21822.
  • 33
    De Galocsy C, Kaufman L, Tomasovic S, Delwaide J, Nevens F. Hepatitis C genotype 4 response rate to pegylated interferon and ribavirin treatment in Belgium is similar to genotype 1. Acta Gastroenterol Belg 2010; 73: 22934.
  • 34
    Dimitroulopoulos D, Elefsiniotis I, Pavlidis C, et al. European vs. Egyptian HCV-4 patients with elevated baseline HCV RNA, treated with PEG-IFN-α2a and ribavirin: the role of rapid and early virologic response. Hepat Mon 2010; 10: 1938.
  • 35
    El-Shazly Y, Rafeek M, Al-Swaff R. Effect of well controlled diabetes mellitus on sustained virologic response in chronic HCV genotype 4 infected patients. J Diabetol 2012; 16.
  • 36
    El Khayat HR, Fouad YM, El Amin H. A randomized trial of 24 versus 48 weeks of peginterferon a-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response. Trop Gastroenterol 2012; 33: 1127.
  • 37
    Urquijo JJ, Diago M, Boadas J, et al. Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4. Ann Hepatol 2013; 12: 305.
  • 38
    Alfaleh FZ, Hadad Q, Khuroo MS, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004; 24: 56874.
  • 39
    Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 85866.
  • 40
    Derbala M, AmerA, BenerA, et al. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005; 12: 3805.
  • 41
    Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14: 4607.
  • 42
    Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007; 46: 173240.
  • 43
    Elefsiniotis IS, Vezali E, Mihas C, Saroglou G. Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Intervirology 2009; 52: 24751.
  • 44
    Ghaffar TYA, El Naghy S, El Sebaie H, El Monaiery M, Ghaffar AYA. Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. Indian J Pediatr 2009; 76: 8958.
  • 45
    Al Ali J, Owayed S, Al-Qabandi W, Husain K, Hasan F. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann Hepatol 2010; 9: 15660.
  • 46
    Khattab MA, Abdel-fattah ME, Eslam M, et al. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy. J Clin Gastroenterol 2010; 44: 70712.